Head-To-Head Analysis: Kyntra Bio (NASDAQ:KYNB) and Atara Biotherapeutics (NASDAQ:ATRA)

Atara Biotherapeutics (NASDAQ:ATRA) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations.

Earnings & Valuation

This table compares Atara Biotherapeutics and Kyntra Bio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77 million	0.73	$32.69 million	($1.18)	-7.47
Kyntra Bio	$6.44 million	4.36	$183.45 million	$45.30	0.15

Kyntra Bio has lower revenue, but higher earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Atara Biotherapeutics and Kyntra Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%
Kyntra Bio	2,199.13%	N/A	-47.27%

Volatility and Risk

Atara Biotherapeutics has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Atara Biotherapeutics and Kyntra Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1	1	1	1	2.50
Kyntra Bio	1	1	4	0	2.50

Atara Biotherapeutics presently has a consensus price target of $9.50, indicating a potential upside of 7.83%. Kyntra Bio has a consensus price target of $37.25, indicating a potential upside of 436.74%. Given Kyntra Bio’s higher possible upside, analysts plainly believe Kyntra Bio is more favorable than Atara Biotherapeutics.

Summary

Kyntra Bio beats Atara Biotherapeutics on 11 of the 14 factors compared between the two stocks.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.